Ipsen SA ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $33.8333
- Today's High:
- $33.86
- Open Price:
- $33.86
- 52W Low:
- $21.9562
- 52W High:
- $33.86
- Prev. Close:
- $32.605
- Volume:
- 541
Company Statistics
- Market Cap.:
- $10.80 billion
- Book Value:
- 10.2898
- Revenue TTM:
- $3.28 billion
- Operating Margin TTM:
- 26.54%
- Gross Profit TTM:
- $2.63 billion
- Profit Margin:
- 13.7%
- Return on Assets TTM:
- 9.39%
- Return on Equity TTM:
- 12.52%
Company Profile
Ipsen SA ADR had its IPO on under the ticker symbol IPSEY.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Ipsen SA ADR has a staff strength of 5,300 employees.
Stock update
Shares of Ipsen SA ADR opened at $33.86 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $33.83 - $33.86, and closed at $33.83.
This is a +3.77% increase from the previous day's closing price.
A total volume of 541 shares were traded at the close of the day’s session.
In the last one week, shares of Ipsen SA ADR have increased by +6.28%.
Ipsen SA ADR's Key Ratios
Ipsen SA ADR has a market cap of $10.80 billion, indicating a price to book ratio of 2.7317 and a price to sales ratio of 2.7217.
In the last 12-months Ipsen SA ADR’s revenue was $3.28 billion with a gross profit of $2.63 billion and an EBITDA of $1.06 billion. The EBITDA ratio measures Ipsen SA ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ipsen SA ADR’s operating margin was 26.54% while its return on assets stood at 9.39% with a return of equity of 12.52%.
In Q2, Ipsen SA ADR’s quarterly earnings growth was a negative -50.4% while revenue growth was a positive 8.4%.
Ipsen SA ADR’s PE and PEG Ratio
- Forward PE
- 11.534
- Trailing PE
- 24.8893
- PEG
- 0
Its diluted EPS in the last 12-months stands at $1.31 per share while it has a forward price to earnings multiple of 11.534 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ipsen SA ADR’s profitability.
Ipsen SA ADR stock is trading at a EV to sales ratio of 2.588 and a EV to EBITDA ratio of 7.0778. Its price to sales ratio in the trailing 12-months stood at 2.7217.
Ipsen SA ADR stock pays annual dividends of $1.2 per share, indicating a yield of 0.98% and a payout ratio of 23.39%.
Balance sheet and cash flow metrics
- Total Assets
- $6.09 billion
- Total Liabilities
- $1.71 billion
- Operating Cash Flow
- $-89300000.00
- Capital Expenditure
- $24.10 million
- Dividend Payout Ratio
- 23.39%
Ipsen SA ADR ended 2024 with $6.09 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.09 billion while shareholder equity stood at $3.40 billion.
Ipsen SA ADR ended 2024 with $0 in deferred long-term liabilities, $1.71 billion in other current liabilities, 83800000.00 in common stock, $195.20 million in retained earnings and $681.00 million in goodwill. Its cash balance stood at $413.40 million and cash and short-term investments were $438.10 million. The company’s total short-term debt was $1,200,000 while long-term debt stood at $0.
Ipsen SA ADR’s total current assets stands at $1.76 billion while long-term investments were $0 and short-term investments were $24.70 million. Its net receivables were $685.60 million compared to accounts payable of $746.60 million and inventory worth $350.00 million.
In 2024, Ipsen SA ADR's operating cash flow was $-89300000.00 while its capital expenditure stood at $24.10 million.
Comparatively, Ipsen SA ADR paid $0.23 in dividends in 2024.
Other key metrics
- Current Trading Price
- $33.83
- 52-Week High
- $33.86
- 52-Week Low
- $21.9562
- Analyst Target Price
- $
Ipsen SA ADR stock is currently trading at $33.83 per share. It touched a 52-week high of $33.86 and a 52-week low of $33.86. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $31.4 and 200-day moving average was $29.05 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0.9% are held by institutions.
Frequently Asked Questions About Ipsen SA ADR
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.